Avant Technologies Inc Stock Price, News & Analysis

Avant Technologies (OTCQB: AVAI) announced that Vinicio Vargas, CEO of their joint venture partner Ainnova Tech, presented at Roche's Latin America "Macular Spectacular" Ophthalmology conference in Colombia. The conference focused on scientific advances in treating common eye diseases and fostering regional collaboration.

Notably, Ainnova formed a strategic alliance with Roche and Salud 360 in Q4 2024 to launch a pilot program using their AI-powered Vision AI technology to combat diabetic retinopathy. If successful, the program could expand to the United States, Canada, and Europe through Ai-nova Acquisition Corp. (AAC), which holds worldwide licensing rights for Ainnova's technology portfolio.

Avant Technologies (OTCQB: AVAI) and its joint venture partner Ainnova Tech have completed a crucial pre-submission meeting with the FDA regarding their Vision AI platform for early detection of diabetic retinopathy. The meeting provided essential guidance for their upcoming U.S. clinical trial, including protocol requirements and necessary resources.

Through their joint venture company Ai-nova Acquisition Corp. (AAC), which holds worldwide licensing rights to Ainnova's technology portfolio, the companies are preparing to conduct data collection across U.S. primary care clinics. The study will compare their AI-based retinal screening against readings from three retinologists. The trial's success is crucial for obtaining FDA 510(k) clearance to market the technology in the United States.

Avant Technologies (OTCQB: AVAI) and its joint venture partner Ainnova Tech have launched an innovative preventive care model in Latin America, focusing on diabetic patients. The model provides free retinal risk screenings at local pharmacies, shifting care from hospitals to convenient locations.

The initiative integrates key healthcare stakeholders including pharmacy chains, health clinics, insurance companies, and pharmaceutical partners. Ainnova's AI platform identifies at-risk patients before symptoms appear, enabling early intervention and better clinical outcomes.

Through Ai-Nova Acquisition Corp. (AAC), the companies hold worldwide licensing rights for Ainnova's technology portfolio. The company projects significant revenue growth for 2025 and 2026 as commercial agreements and pilot programs expand across multiple countries.

Avant Technologies (OTCQB: AVAI) and its joint venture partner Ainnova Tech are preparing for a crucial FDA pre-submission meeting scheduled for July 7, 2025. The meeting will focus on discussing the planned clinical trial of Ainnova's Vision AI platform for early detection of diabetic retinopathy.

Through their partnership company Ai-nova Acquisition Corp. (AAC), which holds worldwide licensing rights to Ainnova's technology portfolio, the companies aim to determine critical trial parameters including the number of clinical sites and total patients needed. The pre-submission meeting will be instrumental in obtaining FDA 510(k) clearance to market the Vision AI technology in the United States.

The technology aims to address diabetic retinopathy, the leading cause of preventable blindness worldwide, with potential applications in early detection of other conditions such as Alzheimer's and cardiovascular disease through retinal screening. The FDA engagement is considered crucial for entering the U.S. market and unlocking significant commercial potential.

Avant Technologies (OTCQB: AVAI) announced plans to establish a new company focused on diabetes treatment expansion. This development follows their successful joint venture with Ainnova Tech through Ai-nova Acquisition Corp (AAC), which utilizes the Vision AI platform for detecting diabetic retinopathy and other diseases.

The company's Vision AI technology can identify early markers of various conditions, including diabetic retinopathy, which affects over 30% of diabetes patients. With over 500 million people globally living with diabetes, Avant aims to expand from diagnosis to treatment through potential joint ventures, partnerships, or acquisitions.

Avant Technologies (OTCQB: AVAI) and its joint venture partner Ainnova Tech announced the launch of diabetic retinopathy screenings in partnership with Grupo Dökka's pharmacy chains Fischel and La Bomba in Central America. The initiative utilizes Ainnova's AI platform, Vision AI, to perform quick, non-invasive retinal scans for early detection of diabetic retinopathy. The program offers free screenings to diabetic customers, aiming to identify retinal changes before they affect vision. CEO Vinicio Vargas highlighted plans to expand similar initiatives to Mexico, focusing on integrating pharmaceutical, retail, and ophthalmology services. Grupo Dökka, operating in Costa Rica, Nicaragua, and Panama, plans to expand its healthcare platforms across Central America.

Avant Technologies (OTCQB:AVAI) and Ainnova Tech are finalizing a prototype of their proprietary automated retinal camera through their joint venture, Ai-nova Acquisition Corp (AAC). The new device aims to disrupt the market with a significantly lower cost compared to existing fundus cameras while offering seamless integration with Ainnova's Vision AI software platform. The Vision AI platform can detect early markers of various diseases including diabetic retinopathy, glaucoma, macular edema, age-related macular degeneration, cardiovascular disease, type 2 diabetes, liver fibrosis, and chronic kidney disease. The automated camera will capture and upload images to the Vision AI platform, which generates risk reports within seconds. AAC holds global licensing rights for developing, maintaining, and marketing Ainnova's technology portfolio.

Avant Technologies (OTCQB: AVAI) has signed a non-binding letter of intent (LOI) for a business combination with Ainnova Tech, a healthcare technology company specializing in AI-powered early disease detection. The merger would integrate 100% of Ainnova's equity into the combined public company, with the final structure pending due diligence. The companies expect to announce a definitive agreement by early next quarter, subject to various approvals. This merger builds on their existing joint venture through Ai-nova Acquisition Corp., formed in late 2024. The timing aligns with their upcoming FDA pre-submission meeting in July regarding Ainnova's Vision AI platform for diabetic retinopathy detection. The merger aims to streamline technology commercialization and enhance shareholder value by combining their AI healthcare capabilities.

Avant Technologies (OTCQB: AVAI) and Ainnova Tech are finalizing a prototype of a low-cost automated retinal camera that integrates with Ainnova's Vision AI platform. The camera will automatically capture and upload retinal images to the AI platform, which generates risk reports within seconds. The Vision AI software can detect multiple diseases including diabetic retinopathy, glaucoma, macular edema, cardiovascular disease, type 2 diabetes, liver fibrosis, and chronic kidney disease. While Vision AI currently works with any fundus camera, this proprietary device aims to provide a cost-effective, user-friendly solution for market entry and capture. The development is being conducted through Ai-nova Acquisition Corp. (AAC), a joint venture between Avant and Ainnova, which holds global licensing rights for Ainnova's technology portfolio.